Skip to main content

Advertisement

SpringerLink
Log in

Understanding Less Common Ovarian Cancers (LCOCs): Updated Review and Management Strategies

  • Review article
  • Published:
Indian Journal of Gynecologic Oncology Aims and scope Submit manuscript

Abstract

Standard protocols for the management of less common ovarian cancers (LCOCs) are still evolving. To date, all histologic entities of ovarian cancers have been managed with similar strategies as used for high-grade serous tumors. However, emerging data suggests that LCOCs are separate entities each possessing distinct clinical behavior and molecular profile. Good quality evidence for the management of these tumors is limited by small study population, less cost-effective studies, long recruitment times and less prioritization in funding. Growing evidence suggests that there is better overall outcome for patients with LCOCs who are being managed in large centers with adequate expertise and experience. With the expansion of paradigm of knowledge on molecular profiles in cancer research and development of newer drugs targeting distinct cellular pathways, there is upcoming data showing benefits of newer drugs as effective treatments for LCOCs. This updated review will outline important clinical features, molecular profiles, management strategies and recent developments in the treatment of LCOCs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–14.

    Article  PubMed  Google Scholar 

  2. Wang S, Qiu L, Lang JH, Shen K, Yang JX, Huang HF, et al. Clinical analysis of ovarian epithelial carcinoma with coexisting pelvic endometriosis. Am J Obstet Gynecol. 2013;208(5):413.e1-5.

    Article  PubMed  Google Scholar 

  3. Aysal A, Karnezis A, Medhi I, Grenert JP, Zaloudek CJ, Rabban JT. Ovarian endometrioid adenocarcinoma: incidence and clinical significance of the morphologic and immunohistochemical markers of mismatch repair protein defects and tumor microsatellite instability. Am J Surg Pathol. 2012;36(2):163–72.

    Article  PubMed  Google Scholar 

  4. Zhou J, Shan G, Chen Y. The effect of lymphadenectomy on survival and recurrence in patients with ovarian cancer: a systematic review and meta-analysis. Jpn J Clin Oncol. 2016;46(8):718–26.

    Article  PubMed  Google Scholar 

  5. Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, et al. Ovarian cancer, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw JNCCN. 2021;19(2):191–226.

    Article  CAS  PubMed  Google Scholar 

  6. Köbel M, Kalloger SE, Huntsman DG, Santos JL, Swenerton KD, Seidman JD, et al. Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol. 2010;29(3):203–11.

    Article  PubMed  Google Scholar 

  7. Gershenson DM, Sun CC, Wong KK. Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum. Br J Cancer. 2015;113(9):1254–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Della Pepa C, Tonini G, Santini D, Losito S, Pisano C, Di Napoli M, et al. Low grade serous ovarian carcinoma: from the molecular characterization to the best therapeutic strategy. Cancer Treat Rev. 2015;41(2):136–43.

    Article  CAS  PubMed  Google Scholar 

  9. Kaldawy A, Segev Y, Lavie O, Auslender R, Sopik V, Narod SA. Low-grade serous ovarian cancer: a review. Gynecol Oncol. 2016;143(2):433–8.

    Article  PubMed  Google Scholar 

  10. Gourley C, Farley J, Provencher DM, Pignata S, Mileshkin L, Harter P, et al. Gynecologic cancer intergroup (GCIG) consensus review for ovarian and primary peritoneal low-grade serous carcinomas. Int J Gynecol Cancer. 2014;24(9 Suppl 3):S9–13.

    Article  PubMed  Google Scholar 

  11. Gershenson DM, Bodurka DC, Coleman RL, Lu KH, Malpica A, Sun CC. Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum. J Clin Oncol. 2017;35(10):1103–11.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Grisham RN, Iyer G, Sala E, Zhou Q, Iasonos A, DeLair D, et al. Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer. Int J Gynecol Cancer. 2014;24:1010–4.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Dalton HJ, Fleming ND, Sun CC, Bhosale P, Schmeler KM, Gershenson DM. Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: a single institution experience. Gynecol Oncol. 2017;145(1):37–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Farley J, Brady WE, Vathipadiekal V, Lankes HA, Coleman R, Morgan MA, et al. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol. 2013;14(2):134–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Gershenson DM, Miller A, Brady WE, Paul J, Carty K, Rodgers W, et al. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. Lancet. 2022;399(10324):541–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Chan JK, Teoh D, Hu JM, Shin JY, Osann K, Kapp DS. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol. 2008;109(3):370–6.

    Article  PubMed  Google Scholar 

  17. WHO Classification of Tumours Editorial Board. Female genital tumours. Lyon (France): International Agency for Research on Cancer; 2020. (WHO classification of tumours series, 5th ed.; vol. 4). https://publications.iarc.fr/592.

  18. Fadare O, Zhao C, Khabele D, Parkash V, Quick CM, Gwin K, et al. Comparative analysis of napsin A, alpha-methylacyl-coenzyme A racemase (AMACR, P504S), and hepatocyte nuclear factor 1 beta as diagnostic markers of ovarian clear cell carcinoma: an immunohistochemical study of 279 ovarian tumours. Pathology (Phila). 2015;47(2):105–11.

    CAS  Google Scholar 

  19. Jones S, Wang TL, Shih IM, Mao TL, Nakayama K, Roden R, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Sci. 2010;330(6001):228–31.

    Article  ADS  CAS  Google Scholar 

  20. Mahdi H, Moslemi-Kebria M, Levinson KL, Gojayev A, Lockhart D, Ali-Fehmi R, et al. Prevalence and prognostic impact of lymphadenectomy and lymph node metastasis in clinically early-stage ovarian clear cell carcinoma. Int J Gynecol Cancer. 2013;23(7):1226–30.

    Article  PubMed  Google Scholar 

  21. Nasioudis D, Mulugeta-Gordon L, McMinn E, Frey MK, Chapman-Davis E, Holcomb K. Fertility sparing surgery for patients with FIGO stage I clear cell ovarian carcinoma: a database analysis and systematic review of the literature. Int J Gynecol Cancer. 2020;30(9):1372–7.

    Article  PubMed  Google Scholar 

  22. Colombo N, Sessa C, du Bois A, Ledermann J, McCluggage WG, McNeish I, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol. 2019;30(5):672–705.

    Article  CAS  PubMed  Google Scholar 

  23. Farley JH, Brady WE, Fujiwara K, Nomura H, Yunokawa M, Tokunaga H, et al. A phase II evaluation of temsirolimus in combination with carboplatin and paclitaxel followed by temsirolimus consolidation as first-line therapy in the treatment of stage III–IV clear cell carcinoma of the ovary. J Clin Oncol. 2016;34(15_Suppl)):5531–5531.

    Article  Google Scholar 

  24. Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, et al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2015;33(34):4015–22.

    Article  CAS  PubMed  Google Scholar 

  25. Westhoff GL, Fuh KC, Longacre TA, McNally JL, Hsu IC, Kapp DS, Teng N, Chen LM. Radiation therapy for recurrent clear-cell cancer of the ovary. Int J Gynecol Cancer. 2016;26(9):1608–14. https://doi.org/10.1097/IGC.0000000000000810. (PMID: 27575628).

    Article  PubMed  Google Scholar 

  26. Babaier A, Ghatage P. Mucinous cancer of the ovary: overview and current status. Diagnostics. 2020;10(1):52–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer. 2009;115(6):1234–44.

    Article  PubMed  Google Scholar 

  28. Morice P, Gouy S, Leary A. Mucinous ovarian carcinoma. N Engl J Med. 2019;380(13):1256–66.

    Article  CAS  PubMed  Google Scholar 

  29. Perren TJ. Mucinous epithelial ovarian carcinoma. Ann Oncol. 2016;27:i53–7.

    Article  PubMed  Google Scholar 

  30. Chang J, Sharpe JC, A’Hern RP, Fisher C, Blake P, Shepherd J, et al. Carcinosarcoma of the ovary: incidence, prognosis, treatment and survival of patients. Ann Oncol. 1995;6(8):755–8.

    Article  CAS  PubMed  Google Scholar 

  31. Gotoh O, Sugiyama Y, Takazawa Y, Kato K, Tanaka N, Omatsu K, et al. Clinically relevant molecular subtypes and genomic alteration-independent differentiation in gynecologic carcinosarcoma. Nat Commun. 2019;10(1):4965–80.

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  32. Young RH, Goodman A, Penson RT, Russell AH, Uppot RN, Tambouret RH. Case records of the Massachusetts general hospital. Case 8–2010. A 22 year-old woman with hypercalcemia and a pelvic mass. N Engl J Med. 2010;362:1031–40.

    Article  CAS  PubMed  Google Scholar 

  33. Young RH, Oliva E, Scully RE. Small cell carcinoma of the ovary, hypercalcemic type: a clinicopathological analysis of 150 cases. Am J Surg Pathol. 1994;18(11):1102–16.

    Article  CAS  PubMed  Google Scholar 

  34. Tischkowitz M, Huang S, Banerjee S, Hague J, Hendricks WP, Huntsman DG, et al. Small-cell carcinoma of the ovary, hypercalcemic type-genetics, new treatment targets, and current management guidelines. Clin Cancer Res. 2020;26(15):3908–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Lang JD, Hendricks WPD. Identification of driver mutations in rare cancers: the role of SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). Methods Mol Biol. 2018;1706:367–79.

    Article  CAS  PubMed  Google Scholar 

  36. Schultz KAP, Harris AK, Schneider DT, Young RH, Brown J, Gershenson DM, et al. Ovarian sex cord-stromal tumors. J Oncol Pract. 2016;12(10):940–6.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Li J, Bao R, Peng S, Zhang C. The molecular mechanism of ovarian granulosa cell tumors. J Ovarian Res. 2018;11(1):1–8.

    Article  ADS  Google Scholar 

  38. Harbi RA, McNeish IA, El-Bahrawy M. Ovarian sex cord-stromal tumors: an update on clinical features, molecular changes, and management. Int J Gynecol Cancer. 2021;31:161–8.

    Article  PubMed  Google Scholar 

  39. Ray-Coquard I, Morice P, Lorusso D, Prat J, Oaknin A, Pautier P, et al. Non-epithelial ovarian cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv1-18.

    Article  CAS  PubMed  Google Scholar 

  40. Zanagnolo V, Sartori E, Galleri G, Pasinetti B, Bianchi U. Clinical review of 55 cases of malignant ovarian germ cell tumors. Eur J Gynaecol Oncol. 2004;25(3):315–20.

    CAS  PubMed  Google Scholar 

  41. Zhang Y, Staley SA, Tucker K, Clark LH. Malignant Brenner tumor of the ovary: case series and review of treatment strategies. Gynecol Oncol Rep. 2019;12(28):29–32. https://doi.org/10.1016/j.gore.2019.02.003.

    Article  Google Scholar 

Download references

Funding

Nil.

Author information

Authors and Affiliations

  1. All India Institute of Medical Sciences (AIIMS), Rishikesh, India

    Shalini Rajaram, Pallavi Verma, Parmita Tiwari, Ipshita Sahoo & Ayush Heda

  2. Division of Gynecological Oncology, Sir Gangaram Hospital, First Floor, OPD Block BuildingRajinder Nagar, New Delhi, 11060, India

    Rahul D. Modi

Authors
  1. Shalini Rajaram
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rahul D. Modi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pallavi Verma
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Parmita Tiwari
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ipshita Sahoo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ayush Heda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rahul D. Modi.

Ethics declarations

Conflict of interest

There are no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rajaram, S., Modi, R.D., Verma, P. et al. Understanding Less Common Ovarian Cancers (LCOCs): Updated Review and Management Strategies. Indian J Gynecol Oncolog 22, 27 (2024). https://doi.org/10.1007/s40944-023-00796-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s40944-023-00796-4

Keywords

Search

Navigation